A number of listed pharmaceutical companies announced the proposed winning bid for their drug collection.

"Pharmaceutical Network Industry Dynamics" August 20, the third batch of collection in the official Opening of tenders in Shanghai.
a total of 189 enterprises participated in the procurement, resulting in 125 enterprises to be selected, 191 products to be selected, the average price reduction of selected products 53%, to a high decline of 95%.
the same day, there have been a number of listed pharmaceutical companies announced their drug collection to bid.
Shanghai Medicine: 6 varieties of Shanghai Medicine announced on the evening of the 20th that the company's Xinyi balance, Chinese and Western medicine and Traditional Medicine participated in the third batch of national drug centralized procurement bidding work.
The generic drug metformin (0.25g), hydrochloric acid bromine capsules (30mg), ibuprofen slow release capsules (0.3g), right zopi clones (3mg), fluoxetine hydrochloric acid capsules (20mg) and Catopley tablets (12.5mg, 25mg) approved by the new registration classification of chemicals, are to be included in this procurement collection.
it is understood that the total sales revenue of these six varieties in 2019 is about 162 million yuan.
In addition to the above varieties, the company's Shanghai Shanghai Shanghai Pharmaceutical Xinyi Pharmaceutical Co., Ltd.'s hydrochloric acid metformin slow release tablets (0.5g) and the usual drug chloro-nitrogen tablets (25mg) also participated in the auction bid, but was not shortlisted.
2019 sales revenue of non-finalist varieties totaled 75.72 million yuan, accounting for about 0.322% of the company's 2019 industrial sales revenue, which had no significant impact on the company's operating conditions.
Red Day Pharmaceuticals: 1 variety of Red Day Pharmaceuticals announced that the company's products moxisa star chloride injection (commodity name: Anjotai) to be the third batch of national drug collection.
: 2 varieties of Connbe issued a notice shows that the company hydrochloric acid Tansorosin slow release capsules, non-amine tablets to be the third batch of national drug centralized procurement.
data show that the sales revenue of tansorosin hydrochloric acid in 2019 and the first half of 2020 was 237 million yuan and 161 million yuan, respectively, accounting for 6.768 billion yuan of the company's 2019 sales revenue and 3.195 billion yuan of sales revenue in the first half of 2020. 50% and 5.04%, respectively, non-amine tablets in 2019 and the first half of 2020 sales revenue of 997.51 million yuan and 8.4919 million yuan, respectively, accounting for the company's 2019 sales revenue and sales revenue in the first half of 2020 0.15% and 0.27%.
Chijin Pharmaceuticals: 1 variety of Chijin Pharmaceuticals announced on the evening of August 20, the company's holding subsidiary Qianjin Xiangjiang Pharmaceuticals participated in the national drug centralized procurement bidding work, Qianjin Xiangjiang Pharmaceuticals has passed the State Drug Administration's generic drug quality and efficacy consistency evaluation of the generic drug python capsules to be the winning bid this centralized procurement, the proposed bid price: 8.63 yuan / 36 grains / box;
2019 sales revenue of 175 million yuan, accounting for 4.95 percent of the company's 2019 revenue.
Baiyunshan: 2 varieties of Baiyunshan announcement, Baiyunshan Pharmaceutical Factory and its controlling subsidiary Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd. participated in the joint procurement office organized the third batch of centralized procurement of drugs in the country tender work.
This time a total of hydrochloric acid meghamgang tablets, hydrochloric acid cyclopropane star tablets, sic acid sedina non-tablets and cephalosporine capsules four products to participate in the tender, of which hydrochloric acid mei King Kong tablets, hydrochloric acid cyclopropanes star tablets two products to be selected in this centralized procurement, sourcydina non-tablets, cephalosporine capsules failed to win the bid.
China Resources double crane: 4 varieties of China Resources double crane announcement, the company's wholly-owned subsidiary Beijing Wanhui double crane, China Resources Seko to participate in the third batch of centralized procurement of national drugs.
Wanhui Shuanghe and China Resources Seko have passed the State Drug Administration's generic drug quality and efficacy consistency evaluation of the generic drug metformin hydrochloric acid slow release tablets (0.5g), pyrethroids capsules (80mg), non-nachminamide tablets (5mg), Viglitin tablets (50mg) to choose this centralized procurement.
Good Faith Pharmaceuticals: 1 variety of good faith pharmaceutical industry issued the company to participate in the national drug centralized procurement to be the winning announcement, the company hydrochloric acid amino glucose capsules (0.75g) in the national organization of the third batch of drug centralized belt procurement proposed to be the winning bid.
it is learned that amino hydrochloric acid glucose capsules as the company's core products, in 2020 and a half years to achieve revenue of 105 million yuan, accounting for 31.92 percent, of which 0.75g specifications of amino glucose hydrochloride capsules to achieve revenue of 7.1382 million yuan.
According to the company's disclosure announcement, the company intends to bid in the number of 109.9754 million, the proposed winning price of 22.52 yuan / box (30 capsules), a single year is expected to contribute more than 80 million yuan in revenue to the company, accounting for more than 12% of last year's revenue;
Haizheng Pharmaceuticals: 4 varieties of Haizheng Pharmaceuticals announcement, according to the joint procurement of the national drug centralized procurement results announced, the company's products amino sulfate glucose capsules, anaquotine tablets, lactoquer tablets, Trillo tablets to be the winning bid for this centralized procurement, and the company according to the market potential of the provinces for provincial selection, the results of the election was officially released three days later.
it is understood that the company on August 19, 2020 approved by the State Drug Administration issued a "drug registration certificate" for Theguero tablets, so far the variety has not been sold.
according to the IMS database, Tegrelo's global sales for 2019 were $1,915 million, of which $178.6 million was in China, and $523 million in January-March 2020, including $54.552 million in China.
.